CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study.
Wilson D, Pietropaolo S, Acevedo-Calado M, Huang S, Anyaiwe D, Scheinker D, Steck A, Vasudevan M, McKay S, Sherr J, Herold K, Dunne J, Greenbaum C, Lord S, Haller M, Schatz D, Atkinson M, Nelson P, Pietropaolo M. CGM Metrics Identify Dysglycemic States in Participants From the TrialNet Pathway to Prevention Study. Diabetes Care 2023, 46: 526-534. PMID: 36730530, PMCID: PMC10020029, DOI: 10.2337/dc22-1297.Peer-Reviewed Original ResearchConceptsOral glucose tolerance testNormal oral glucose tolerance testType 1 diabetesDiabetes-related autoantibodiesGlucose levelsCGM metricsTrialNet PathwayPrevention StudyAbnormal oral glucose tolerance testGlucose valuesGlucose tolerance testContinuous glucose monitoring parametersStage 2 participantsRelatives of individualsCGMS assessmentDysglycemic statesTolerance testIdentification of individualsDiabetesNegative testAutoantibodiesProgressionBaseline dataIndividualsParticipants